Mylan’s Remdesivir Lyophilized Powder for Injection Receives the DCGI Accelerated Approval for Restricted Emergency Use in COVID-19 Patients in India

 Mylan’s Remdesivir Lyophilized Powder for Injection Receives the DCGI Accelerated Approval for Restricted Emergency Use in COVID-19 Patients in India

Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize Novartis’ Products for $463M

Shots:

  • Mylan’s Remdesivir 100mg/vial Lyophilized Powder for Injection will be launched in India under brand name Desrem in Jul with INR 4,800 which is 80% less to the price of its branded version
  • The company will manufacture the product in its injectables facilities in India, which is also inspected by the US FDA for compliance with good manufacturing practices and will be marketed in 127 markets in India
  • Remdesivir is an investigational drug targeted for COVID-19 and has demonstrated favorable outcomes in two P-III trials. Additionally, the US FDA granted EUA to treat hospitalized patients with severe COVID-19 based on the two P-III trials results in the US also recommended for compassionate use in EU including Japan, Taiwan, and Singapore

Click here to read full press release/ article | Ref: PRNewswire | Image: PharmaWorld

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post